China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational Study
← catalyst calendarNCT07783737 · readout in 1,435 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
300estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-25
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-24 | estimated | When the study began enrolling |
| Primary completion | 2030-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glomerulonephritis Kidney Transplant
Primary outcomes
what the primary-completion date above is the date OFTo assess the incidence of GN recurrence after kidney transplantation and its influencing factors
measured 3-year follow-up
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
measured 3-year follow-up
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
measured 3-year follow-up
Related
AZN · their whole pipeline · Congress trades in AZN
AZN's other studiesmost recently updated first
- Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Phase 4 · Active, not recruiting
- Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) Phase 3 · Recruiting
- Real-World Treatment Study of Koselugo (Selumetinib) — · Recruiting
- Fasenra Pediatric Japan Post-Marketing Study(PMS) — · Active, not recruiting
- AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database — · Recruiting
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed